A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies
Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.
Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients…
Welcome to our interactive training module. Please select from below to
